At eFFECTOR Therapeutics, we possess an unrelenting drive to improve outcomes for patients with cancer.
STRIs simultaneously block production of multiple disease-driving proteins as a single drug. This is possible through targeting a central node (eIF4F) where two major cancer signaling pathways converge and activate a burst of protein synthesis that drives multiple disease processes.
In cancer, processes that are normally tightly controlled become dysregulated, including translation. This leads to the aberrantly high production of multiple proteins that cause uncontrolled growth, immune evasion and metastasis. We believe that our STRIs can inhibit the production of key disease-driving proteins, which tumors have hijacked for their benefit, all while preserving the cell’s normal, healthy state. Our STRIs, which can be synergistic with existing therapies and those in development, are specifically designed to block production of oncoproteins, immune suppression factors and resistance mechanisms that cancer uses to evade therapeutic intervention.
Our leadership team’s in-depth understanding of translation regulation biology and oncology drug development is matched by our expertise in building and leading life science companies. This has given us our key advantage in pioneering the emerging field of translation regulation therapeutics and developing first-in-class agents in this pathway.